Why FDA Called This Meeting

Listeria monocytogenes is the fourth-leading cause of death from foodborne illness in the U.S. — and unlike a lot of foodborne pathogens, it's genuinely one of the deadlier ones: listeriosis cases have held steady at roughly 1,200 a year for over a decade, with a fatality rate around 20%. FDA's own framing was blunt: despite real scientific advances in detection and prevention, the numbers simply haven't moved, which means the current approach isn't working well enough on its own.

If that sounds abstract, it isn't to anyone who's read this blog for a while. Listeria is exactly what showed up in the Made Fresh Salads deli recall I covered back in September, and again in Part 9's double recall of a pasta brand and an imported guanciale within nine days of each other. It's also the pathogen behind one of the bigger outbreaks of the past year: a nationwide listeriosis outbreak tied to Nate's Fine Foods pre-made pasta meals — sold under brands including Home Chef, Marketside, and Trader Joe's — that caused 27 hospitalizations and 7 deaths across 19 states before CDC closed the investigation in February 2026. That's the backdrop this meeting sat against.

What Actually Happened Over the Two Days

FDA held the meeting August 18–19, 2026, both in person and virtually, at the Harvey W. Wiley Federal Building in College Park, Maryland. The room included domestic and foreign government agencies, food and equipment manufacturers and trade groups, consumer groups, standard-setting bodies, physicians, academic researchers, and FDA's own staff.

  • Day 1 covered advances in understanding and controlling the pathogen itself, best practices in prevention, and a long public listening session.
  • Day 2 covered dose-response modeling, food safety management systems for retail environments, and prevention strategies for an era of changing demographics and dietary patterns — plus a second listening session.

FDA has since posted the full agenda, speaker biographies, presentation slides from both days, and complete video recordings of both sessions on the public meeting page, linked in Sources below if you'd rather watch the raw discussion yourself than take my summary of it.

The Real Debate: Is "Zero Tolerance" Actually Working?

This is the part I found most interesting, and it's not what I expected going in. Several speakers pushed back — respectfully, but directly — on how the industry currently treats any Listeria detection at all.

On environmental monitoring: one researcher described a facility that changed how it approached environmental sampling and went from finding zero positives to finding three. The point wasn't that the facility got dirtier — it's that a lot of "clean" results across the industry likely reflect under-testing rather than an actual absence of the pathogen. Facilities built to find contamination, not just to avoid reporting it, get more honest results.

On "zero tolerance": dose-response modeling presented at the meeting argued that low-level contamination carries much lower real-world risk than a strict zero-tolerance policy assumes. One consultant pointed to a 2015 ice cream outbreak where an estimated 15 million contaminated servings circulated — yet the actual number of illnesses was far lower than a zero-tolerance risk model would have predicted, supporting the idea that "low dose equals low risk" at a population level.

On fundamentals: multiple speakers cautioned against letting advanced tools like genomic sequencing overshadow the basics — sanitation, moisture management, temperature control, and hygienic equipment design. In other words: the fancy tools help, but they don't replace the boring stuff.

Why this matters even if you're not in food manufacturing: the reason Listeria keeps turning up in deli meats, soft cheeses, sprouts, and ready-to-eat salads — the exact products in nearly every recall I've covered — is that it survives refrigeration and can grow slowly in cold storage. A facility that tests more aggressively and finds more Listeria isn't necessarily a worse facility; it may just be a more honest one.

What FDA Wants Going Forward

The meeting pushed toward a "seek and destroy" mindset — encouraging companies to test more aggressively without treating every positive result as a punishable failure, since that's what discourages honest testing in the first place. FDA named four priority areas going forward: controlling the pathogen during manufacturing and processing, managing it in ready-to-eat foods at retail, preventing contamination during consumer storage at home, and increasing awareness among at-risk populations — pregnant people, older adults, and anyone immunocompromised, who face the highest risk of severe illness from listeriosis.

How to Weigh In (or Just Watch)

This isn't closed-door policy — FDA is taking public comment on the key questions raised at the meeting through November 2, 2026, via the public docket (FDA-2026-N-7914) on regulations.gov, or by mail to FDA's Dockets Management Staff. And if you want the unfiltered version instead of my summary, both full-day recordings are posted publicly — links below.

Meeting materials last updated by FDA on September 25, 2026.